Advanced Solid Tumors
Conditions
Brief summary
Part A: The purpose of this study is to find the maximum tolerated dose of BMS-777607 in subjects with advanced or metastatic solid tumors Part B: The purpose of this study is to describe the preliminary activity of BMS-77607 in subjects with advanced or metastatic gastroesophageal cancer, hormone refractory prostate cancer, head and neck squamous cell carcinoma, and type I papillary renal cell carcinoma
Interventions
DRUGBMS-777607
Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation
Sponsors
Bristol-Myers Squibb
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Part A: * Subjects with advanced or metastatic solid tumors who have either progressed on standard therapy or for whom standard therapy is not known Part B: * Subjects with advanced or metastatic gastroesophageal cancer, HRPrC, HNSCC, or PRCC who have either progressed on standard therapy, or for whom standard therapy is not known. Eighteen (18) subjects each with gastroesophageal cancer, HRPrC, and HNSCC will be treated. Subjects with PRCC (up to 18) will be enrolled as feasible * Tumor paraffin tissue block or 6-10 unstained slides from the tumor tissue block must be provided * Subjects with HRPrC must have either measurable disease or rising PSA levels (≥3 consecutive rising levels with at least 1 week interval and with PSA level ≥5 mg/ml). All other subjects must have measurable disease as assessed by CT or MRI
Exclusion criteria
* Know brain metastases * Uncontrolled or significant cardiovascular disease * Retinal atrophy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and efficacy assessment including vitals signs, physical assessments, and blood tests | will be conducted weekly for the first 3 weeks then every 3 weeks. All assessments will continue for at least 24 months |
| Tumor assessments | will be conducted every 6 weeks. All assessments will continue for at least 24 months |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics (PK) of BMS-777607 and its N-oxide metabolite, BMS-797669 | will be assessed once weekly for the first 3 weeks |
| The effects of BMS-777607 on blood pressure (BP), heart rate (HR) | will be assessed once weekly for the first 3 weeks then every 3 weeks |
| Effects on electrocardiogram (ECG), PR interval | will be assessed at base line, at week 3 and at end of treatment |
| Effects on left ventricular function | will be assessed at baseline and every 3 weeks for 1st 6 weeks then once every 6 months |
Countries
Australia
Outcome results
None listed